The agonizing itching is one of the most difficult symptoms to bear in patients with primary biliary cholangitis (PBC). It can have a far greater impact on everyday life, sleep and mental stability than the laboratory values of the underlying disease. New studies and congress papers from 2025 show that the therapeutic spectrum has expanded significantly in recent years. The focus today is on the targeted modulation of cholestatic mechanisms, in particular through inhibitors of bile acid transport and PPAR agonists, which not only have a favorable effect on the course of the disease but also on the symptom burden.
Autoren
- Tanja Schliebe
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Itching in primary biliary cholangitis
When the skin becomes agony
- TREATswitzerland Register
Evaluation of system therapies for AD
- Cardiogenic shock - 2025 update
Between standardization, team processes and targeted cycle support
- Collagenoses
Scleroderma – Current recommendations for diagnosis and therapy 2025
- Multiple sclerosis
Avoiding the nocebo trap with natalizumab biosimilars
- COPD and comorbidities
Exacerbation frequency is associated with cardiopulmonary disease burden
- Multiple myeloma
DREAMM-8: Key study in the development of BCMA therapy up to DREAMM-14
- Catheter ablation for atrial fibrillation 2025